Nasdaq Inc vs Smith & Nephew plc — how do they compare? Nasdaq Inc trades at $93.65 (market cap $51.63B), while Smith & Nephew plc trades at $27.21 (market cap $11.10B). The key difference: Nasdaq Inc is far larger — about 4.7× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Nasdaq Inc for 126 Days and Smith & Nephew plc for 121 Days on average.
| NDAQ | SNN | |
|---|---|---|
Market Cap | $51.63B | $11.10B |
Volume | 2,668,175 | 1,051,703 |
Sector | Financials | Health |
52-Week High | $100.98 | $37.17 |
52-Week Low | $76.85 | $26.42 |
Typical Hold Time | 126 Days | 121 Days |
Enterprise Value | $58.09B | $14.13B |
Dividend Yield | 1.26% | 2.95% |
Signals from Pluang's Aura AI — not financial advice
Nasdaq Inc. (NDAQ) trades at $93.65, up 1.87% on the day, reflecting strong momentum. The stock exhibits a bullish technical signal with moving averages supporting further upside, while recent earnings beats and a 22.52% net income margin highlight robust profitability. Positive news includes the addition of Moderna to the Nasdaq-100 Index and HSBC adopting Nasdaq's Calypso platform, signaling business growth.
Outlook remains favorable with a consensus price target of $110.43, implying 18% upside. Key risks include cash flow volatility and high debt levels, but analyst sentiment is strongly bullish with 61% buy ratings. Revenue growth and AI-driven platform adoption present opportunities, though market volatility and competitive pressures warrant monitoring.
Smith+Nephew (SNN) trades at $27.24, near its 52-week low of $27.05, with a bearish technical signal despite recent earnings beats. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%, but the stock faces headwinds from analyst downgrades and CFO departure news. Product launches like the EVOS PELVIC System highlight innovation, yet investor sentiment remains cautious.
The outlook is mixed: strong fundamentals and undervaluation (P/E 18.34) offer upside, but technical weakness and competitive risks temper near-term gains. Key risks include execution challenges and market volatility, while institutional interest (e.g., BlackRock's $505M stake) provides support. Investors should weigh solid profitability against sentiment-driven price pressure.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →